Eli Lilly stock slips as FDA drops suicide warning for Zepbound; traders eye orforglipron, earnings next
Eli Lilly shares fell about 0.4% Wednesday after the FDA ordered drugmakers to remove suicidality warnings from obesity drugs including Zepbound. The FDA said its review found no increased risk of suicidal thoughts with GLP-1 drugs. Investors are watching for updates on Lilly’s oral obesity pill ahead of the Feb. 4 earnings call.